Perrigo Company plc

NYSE:PRGO

Drug Manufacturers - Specialty & Generic

Healthcare
$16.94 -1.97%

-$0.20 today

Market cap
$2.35B
Beta
0.52
P/E (TTM)
-0.8
EPS (TTM)
-$13.10
Dividend yield
11.65%
52W Low $9.23High $28.44

Volume 2.57M

Average 2.96M

PRGO EBITDA Margin

EBITDA as a percentage of revenue.

Perrigo Company plcNYSE: PRGO

EBITDA Margin · Q2 FY2026 · quarter ended Jun 2026

EBITDA Margin widens to 31.6%

EBITDA Margin was 31.6% in Q2 FY2026, up 19.3 pp from a year earlier. On a trailing-twelve-month basis it was -25.2%, down 39.4 pp year over year. Over 3 fiscal years it narrowed by 26.7 pp.

Context

  • EBITDA Margin widened in 1 of the last 3 fiscal years.
  • FY2025 was the lowest level in the 4 fiscal years shown.

What to watch

Whether EBITDA Margin reaches the consensus estimate from 2 analysts of 21.6% for the fiscal year ending Dec 2026, up from -18.8% in FY2025.

Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.

Latest quarterJun 2026
31.6%+60.9 pp QoQ
Last fiscal yearDec 2025
-18.8%-28.7 pp YoY
LTMJun 2026
-25.2%-39.4 pp YoY
EBITDA Margin past and forecast change by horizon
Horizon Past Forecast Difference
Quarter+19.3 pp+5.7 pp-13.7 pp
1 year-28.7 pp+40.3 pp+69.0 pp
3 years-26.7 pp+40.1 pp+66.8 pp
5 years+39.6 pp—
10 years——

Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.

EBITDA Margin history

Percent of revenue · from the income statement

Latest · FY2025
-18.8%
Year-over-year change
-28.7pp
Reported Analyst consensus estimate Further estimates hidden. Sign in to unlock

EBITDA Margin vs competitors

How PRGO compares with its peers on the latest reported figures

  • PRGO's LTM Jun 2026 EBITDA Margin of -25.2% is the 7th highest of the 10 companies compared; the peer median is -1.2%.
  • Its year-over-year change of -39.4 pp is the 8th highest of 9, against a peer median of +1.5 pp.
  • Over three fiscal years its change of -26.7 pp compares with a peer median of -1.0 pp.
PRGO Competitors Peer median
EBITDA Margin for PRGO and competitors
Company Period LTM level YoY 3-year change
SGRYSurgery Partners, Inc.LTM Sep 202619.9% -5.0 pp-1.0 pp
BHCBausch Health Companies Inc.LTM Jun 202618.9% -14.3 pp-4.5 pp
LIVNLivaNova PLCLTM Sep 202614.0% +20.0 pp-12.4 pp
ATECAlphatec Holdings, Inc.LTM Mar 2026-0.2% +8.0 pp+24.0 pp
HCMHUTCHMED (China) LimitedLTM Jun 2025-1.2% +16.8 pp+86.5 pp
SUPNSupernus Pharmaceuticals, Inc.LTM Jun 2026-1.9% -26.9 pp-17.1 pp
PRGOPerrigo Company plcLTM Jun 2026-25.2% -39.4 pp-26.7 pp
HTFLHeartflow, Inc. Common StockLTM Sep 2026-30.2% +29.3 pp—
TARSTarsus Pharmaceuticals, Inc.LTM Sep 2026-100.7% -80.8 pp+219.4 pp
SRRKScholar Rock Holding CorporationLTM Sep 2026-69878.4% ——
Peer median (excluding PRGO) -1.2%+1.5 pp-1.0 pp

Competitors are the stored peer set for PRGO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue4.14B4.45B4.66B4.37B4.25B
Cost of Revenue2.72B3B2.98B2.83B2.76B
Gross Profit1.42B1.46B1.68B1.54B1.49B
Gross Margin34.2%32.7%36.1%35.3%35.1%
Research & Development122M123.1M122.5M112.2M95.4M
Selling, General & Admin1.11B1.21B1.27B1.11B526.5M
Operating Expenses1.01B1.38B1.53B1.43B1.15B
Depreciation & Amortization312.2M338.6M359.5M325.9M337.5M
EBITDA695.9M355.5M525M433M(797.9M)
EBITDA Margin16.8%8.0%11.3%9.9%-18.8%
Operating Income410.4M78.9M151.9M112.9M343.3M
Operating Margin9.9%1.8%3.3%2.6%8.1%
Interest Income00000
Interest Expense125M156M173.8M187.8M162.5M
Other Income / Expenses(151.7M)(218M)(160.2M)(193.6M)(1.64B)
Income Before Tax258.7M(139.1M)(8.3M)(80.7M)(1.3B)
Pre-Tax Margin6.3%-3.1%-0.2%-1.8%-30.5%
Income Tax Expense389.6M(8.2M)(3.9M)80M104.4M
Net Income(68.9M)(140.6M)(12.7M)(171.8M)(1.43B)
Net Margin-1.7%-3.2%-0.3%-3.9%-33.5%
EPS (Basic)(0.98)(0.97)(0.09)(1.25)(10.29)
EPS (Diluted)(0.98)(0.97)(0.09)(1.25)(10.29)
Weighted Avg Shares133.6M134.5M135.3M137.4M138.5M
Weighted Avg Shares (Diluted)133.6M134.5M135.3M137.4M138.5M

Perrigo Company plc

NYSE:PRGO

Intrinsic Alpha fair value

Locked

Current Price

$16.94

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.